This is a phase Ib, dose escalation study with expansion phase to assess the safety, tolerability, and pharmacokinetics of the encorafenib, binimetinib and palbociclib combination in BRAF-mutant MM (NCT04720768). The gene discussed is BRAF; the disease is Miyoshi myopathy.